Senti Biosciences (SNTI) said Tuesday that its board has authorized a 1-for-10 reverse stock split.
Shares in the biotech firm will begin trading on a split-adjusted basis at the start of trading on Thursday.
The move, which will reduce the number of outstanding shares to about 4.6 million from about 45.8 million, is intended to help Senti comply with Nasdaq's minimum price requirement rule, the company said
Shares of Senti Biosciences were down more than 7% to about $0.29 in early trading.
Price: 0.29, Change: -0.02, Percent Change: -7.88
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments